BACKGROUND Single nucleotide polymorphism in the interleukin28B (IL28B) gene was recently shown to be associated with a significant increase in response to interferon-α and ribavirin treatment in patients with chronic hepatitis C. Similarly, thyroid disease (TD) occurring during treatment confer an improved sustained virologic response (SVR). OBJECTIVES To determine the role of IL28B genotype...

conclusions examination of the fasting lipid profile has clinical importance in predicting the efficacy of peg-ifn-α-2b plus rbv combination therapy for patients with hcv g1b even after the discovery of the il28 genotype as a potent predictive factor. objectives to re-examine the significance of lipoprotein profiles on virological response to peg-ifn plus rbv combination therapy in patients wit...

BACKGROUND The hepatitis C virus (HCV) infection has been identified as a leading cause of progressive liver diseases worldwide. Despite new treatment strategies, pegylated interferon alfa-2a (Peg-IFNα-2a), in combination with ribavirin (RBV), still represents the gold standard of therapy for hepatitis C in developing countries. OBJECTIVES The aim of this study was to investigate the associat...

background: single nucleotide polymorphism in the interleukin28b (il28b) gene was recently shown to be associated with a significant increase in response to interferon-α and ribavirin treatment in patients with chronic hepatitis c. similarly, thyroid disease (td) occurring during treatment confer an improved sustained virologic response (svr). objectives: to determine the role of il28b genotype...

BACKGROUND Interleukin (IL) 28B single nucleotide polymorphisms can predict sustained virological response (SVR) in hepatitis C virus (HCV) patients following pegylated interferon-alpha (PEG IFN-α) and ribavirin treatment. AIM To design a meta-analysis to determine IL28B genotypes', rs12979860 CC and rs8099917 TT, correlation with SVR in PEG IFN-α/ribavirin-treated HCV patients. METHODS Met...

BACKGROUND Abnormal serum lipid profiles have been noted in patients with chronic hepatitis C virus (HCV) infection. Moreover, many reports suggest that serum lipoprotein profiles are more profoundly distorted in patients with HCV G1b infection who have an unfavorable response to pegylated interferon (peg-IFN) plus ribavirin (RBV) combination therapy. However, after the discovery of single nucl...